CSDA Frequently Asked Questions
Who is eligible to apply?
The Clinical Scientist Development Award provides grants to junior physician-scientist faculty in order to facilitate careers in clinical research and transition into independent funding. Below are the minimum requirements for applicants for reference, however the full set of eligibility criteria are indicated in the request for proposals for each competition:
- Must hold a title of Instructor or Assistant Professor at a US-based, accredited academic institution equivalent to at least one year to a maximum of five years
- At the time of application, cannot be recipient of NIH R01 award (please see the Other Funding section below for more details on exclusion criteria for funding)
Length of Time of Award
How many years does the CSDA fund?
The CSDA awards funding for research over the course of three years.
I have a National Institutes of Health K series award, which requires 75 percent research effort. Can I still apply for the CSDA?
An awardee must devote 75 percent of his/her professional time to research, but there is no minimum effort requirement for the CSDA project itself. Holding a K award or other career development award does not preclude the applicant from receiving a CSDA grant.
I have been successful in obtaining other research funding. Will this hurt my chances in getting an award?
No. Candidates will not be penalized for having other career development awards, but there can be no budgetary overlap between the proposed aims of the CSDA research and those of other awards.
I am the principal investigator or co-principal investigator of a National Institutes of Health R01. Can I apply for this award?
No. An award will not be made if the applicant has been or becomes the principal investigator or co-principal investigator on a National Institutes of Health, peer-reviewed, R01 or equivalent research grant on or before the CSDA award start date. This includes but is not limited to: research projects that are part of a P01 program project, P50 center grant or a U01 cooperative agreement, DP1, DP2 R37 and VA Merit grants.
I have a National Institutes of Health K series award or other research support. Can I propose the same scientific aims?
No. The aims proposed on your CSDA application must be distinct from those of other awards, with no budgetary overlap. To avoid conflicts in the event that your proposal receives a funding recommendation, we strongly suggest that you do not propose the same aims and budget in different grant applications.
What is DDCF's definition of clinical research?
Clinical research involves the scientific investigation of the etiology, prevention, diagnosis, or treatment of human disease using human subjects, human populations or materials of human origin. Included in the definition are studies that utilize tissues or pathogens only if they can be linked to a patient.
It is expected that the research protocols of grant applicants will require Institutional Review Board (IRB) approval. Occasionally, the foundation has funded research that does not require IRB approval, such as research using de-identified patient populations. If a research project is being proposed that does not require IRB approval, applicants are strongly encouraged to contact program staff to discuss whether the proposed research falls within the DDCF's definition of clinical research.
In keeping with the wishes expressed in Doris Duke’s will, experiments that use animals or primary tissues derived from animals will not be supported by this program.
Would the public access policy adopted by DDCF limit the journals to which I can submit my DDCF-funded work?
No. The policy only requires that you submit an electronic copy of your final peer‐reviewed manuscripts in the PubMed Central online archive immediately upon acceptance for journal publication. The manuscript will have to be made publicly available in PubMed Central no later than 12 months after the official date of journal publication.
When is Institutional Review Board (IRB) approval or submission required to be in effect—at the time of the full proposal submission or before an award is forthcoming?
IRB approval can be pending at the time of full proposal submissions; however, if you receive a grant, we expect that you will have approval by the start date or no later than two months from the start date.
When is Investigational New Drug (IND) approval required to be in effect—at the time of the full proposal submission or before an award is made?
IND approval can be pending at the time of pre-proposal submission. However, it must be in place by the deadline for the full proposal. Full proposals for projects with IND requirements that do not have approval at the time of submission will be disqualified.
My preliminary research has included research in animal models. Can I include this in my proposal?
Yes. Preliminary research in animal models may be included in your application. However, no DDCF funds may be used for experiments that utilize animals or primary tissues derived from animals. If you are planning animal studies concurrent to your proposed CSDA research and mention these in your proposal, you must clearly state that these will be supported by other funds and include the source of these funds.
What is the success rate for CSDA applicants?
Although there is no way to know how many applications we will receive this year, we can provide an estimate of the success rate based on data from previous competitions. The success rate for applicants in 2016 was 10 percent.
How many awards will be made?
DDCF plans to award approximately 16 grants in 2018.
Who do I contact if I have further questions?
If your question is not answered after reviewing the FAQ’s, email firstname.lastname@example.org with “CSDA” as the subject line. No phone calls please.